Advertisement

Urological Research

, Volume 13, Issue 1, pp 27–34 | Cite as

Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line

  • P. J. Hepburn
  • R. T. D. Oliver
  • P. A. Riley
  • B. T. Hill
  • J. R. W. Masters
Originals

Summary

Many chemotherapeutic drugs have been used to treat patients with advanced bladder cancer, but few of these have been evaluated adequately in phase II clinical trials. Continuous cell lines provide one means for comparing the in vitro cytotoxicities of anticancer agents. In this study, a continuous cell line derived from a transitional cell cancer of the human bladder, which still produces tumours histologically similar to the tumour of origin on xenotransplantation, was used to measure the in vitro cytotoxicities of twelve chemotherapeutic drugs by clonogenic assay. The most cytotoxic agents tested were methotrexate, mitoxantrone, adriamycin, mitomycin C and cisplatin. These in vitro findings are compatible with the activity of these drugs given systemically as single agents in phase II clinical trials in patients with advanced bladder cancer.

Key words

Bladder cancer Continuous cell line Chemotherapy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Achterrath W, Niederle N, Raettig R, Hilgard P (1982) Etoposide—chemistry, preclinical and clinical pharmacology. Cancer Treat Rev 9:Suppl A, 3–13Google Scholar
  2. 2.
    Alberts DS, Chen HSG, Liu R, Himmelstein KJ, Mayersohn M, Perrier D, Gross J, Moon T, Broughton A, Salmon SE (1978) Bleomycin pharmacokinetics in man. I. Intravenous adminsistration. Cancer Chemother Pharmacol 1:177–181Google Scholar
  3. 3.
    Alberts DS, Chen HSG (1980) Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: Salmon SE (ed) Cloning of human tumor stem cells. Alan R Liss Inc, New York, pp 351–359Google Scholar
  4. 4.
    Alberts DS, Chen HSG, Salmon SE (1980) In vitro drug assay—pharmacologic considerations. In: Salmon SE (ed) Cloning of human tumor stem cells. Alan R Liss Inc, New York, pp 197–207Google Scholar
  5. 5.
    Alberts DS, Peng YM, Davis TP (1981) Comparative pharmacology of mitoxantrone and bisantrene. Proc NCI EORTC Symp New Drug Cancer Ther: Abstract 35Google Scholar
  6. 6.
    Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL (1983) Pharmacokinetics of mitoxantrone in patients. Proc 13th Int Congr Chemother, Viema (in press)Google Scholar
  7. 7.
    Balis FM, Holcenberg JS, Bleyer WA (1983) Clinical pharmacokinetics of commonly used anticancer drugs Clin Pharmacokinet 8:202–232Google Scholar
  8. 8.
    Belej MA, Troetel WM, Weiss AJ, Stambaugh JE, Manthei RW (1972) The absorption and metabolism of dibromodulcitol in patients with advanced cancer. Clin Pharmacol Ther 13:563–572Google Scholar
  9. 9.
    Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA, Repta AJ (1979) Pharmacokinetics of non-protein-bound platinum species, following administration of cis-dichlorodiam-mineplatinum (II). Cancer Treat Rep 63:1515–1521Google Scholar
  10. 10.
    Benjamin RS, Riggs CE, Bachur NR (1977) Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37:1416–1420Google Scholar
  11. 11.
    Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA (1971) Methotrexate pharmacokinetic. J Pharm Sci 60:1128–1133Google Scholar
  12. 12.
    Bruce WR, Meeker BE, Valeriote FA (1966) Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37:233–245Google Scholar
  13. 13.
    Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain AH, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckha, MJ, Harrap KR (1982) Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmaco 9:140–147Google Scholar
  14. 14.
    Chabner BA, Donehower RC, Schilsky RL (1981) Clinical pharmacology of methotrexate. Cancer Treat Rep 65, Suppl 1:51–54Google Scholar
  15. 15.
    Crooke ST, Bradner WT (1976) Mitomycin C: a review. Cancer Treat Rev 3:121–139Google Scholar
  16. 16.
    Curt GA, Grygiel JJ, Corden BJ, Ozols RF, Weiss RB, Tell DT, Meyers CE, Collins JM (1983) A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240). Cancer Res 43:4470–4473Google Scholar
  17. 17.
    Dickson C, Elkington J, Hales A, Weiss R (1980) Antibodymediated neutralisation of virus Is abrogated by mycoplasma. Infect Immun 28:649–653Google Scholar
  18. 18.
    D'Incalci M, Farina P, Sessa C, Molina P, Mangioni C, Jancovich M, Masera G, Beer M, Cavalli F (1982) Pharmacokinetic of VP16 in humans. Chemioterapia I:126–129Google Scholar
  19. 19.
    Drewinko B, Roper PR, Barlogie B (1979) Patterns of cell survival following treatment with antitumor agents in vitro. Eur J Cancer 15:93–99Google Scholar
  20. 20.
    Drewinko B, Patchen M, Yang LY, Barlogie B (1981) Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells. Cancer Res 41:2328–2333Google Scholar
  21. 21.
    Dulbecco R, Vogt M (1954) Plaque formation and isolation of pure lines with polimyelitis viruses. J Exp Med 99:167–182Google Scholar
  22. 22.
    Finn C, Sadée W (1975) Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilutionmass fragmentography. Cancer Chemother Rep 59:279–286Google Scholar
  23. 23.
    Fogh J, Fogh H (1964) A method for direct demonstration of pleuropneumonia-like organisms in cultured cells. Proc Soc Exp Biol Med 117:899–901Google Scholar
  24. 24.
    Greene RF, Collins JM, Jekins JF, Speyer JL, Myers CE (1983) Plasma pharmacokinetics of adriamycin and adriamycinol: Implications for the design of in vitro experiment and treatment protocols. Cancer Res 43:3417–3421Google Scholar
  25. 25.
    Hagen K, Daly JJ, Kamali HM, Lin JC, Yu SC, Prout GR (1979) New assay for cytotoxic agents in human bladder cancer. Surg Forum 30:560–562Google Scholar
  26. 26.
    Harker WG, Torti FM (1983) The chemothrapy of bladder carcinoma: Systemic therapy. Recent Results Cancer Res 85:37–49Google Scholar
  27. 27.
    Hastings RJ, Franks LM (1981) Chromosome pattern, growth in agar and tumorigenicity in nude mice of four human bladder carcinoma cell lines. Int J Cancer 27:15–21Google Scholar
  28. 28.
    Hepburn PJ, Masters JRW (1983) The biological characteristics of continuous cell lines derived from human bladder. In: Bryan GT, Cohen SM (eds) The pathology of bladder cancer, vol II. CRC Press Ind, Florida, pp 213–227Google Scholar
  29. 29.
    Hill BT, Baserga R (1975) The cell cycle and its significance for cancer treatment. Cancer Treat Rev 2:159–175Google Scholar
  30. 30.
    Hill BT (1978) Cancer chemotherapy. The relevance of certain concepts of cell cycle kinetics. Biochim Biophys Acta 516:389–417Google Scholar
  31. 31.
    Hill BT, Whelan RDH, Rupniak HT, Dennis LY, Rosholt MS (1981) A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry. Cancer Chemother Pharmacol 7:21–26Google Scholar
  32. 32.
    Hill BT, Whelan RDH (1981) Assessments of the sensitivities of cultured human neuroblastoma cells to anti-tumour drugs. Pediatr Res 15:1117–1122Google Scholar
  33. 33.
    Hill B, Metcalfe S, Hepburn PJ, Masters JRW, Whelan RDH (1983) Evaluation of spirogermanium in murine and human tumour lines in vitro and demonstration of synergy with cisplatin or 5-fluorouracil. Proc 13th Int Congr Chemother, Vienna: Pt 257, 30–33Google Scholar
  34. 34.
    Hill BT, Bellamy AS, Metcalfe S, Hepburn PJ, Masters JRW, Whelan RDH (1984) Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro. Invest New Drugs 2:29–33Google Scholar
  35. 35.
    Hisazumi H, Nakajima K, Uchibayashi T (1983) Chemosensitivity of established human bladder cell lines in vitro. Gann 74:176–182Google Scholar
  36. 36.
    Horváth IP, Csetényi J, Hindy I, Kerpel-Fronius S, Institoris L, Hegedüs L, Eckhardt S (1982) Metabolism and pharmacokinetics of dibromodulcitol (DBD, NSC-104800) in man-II. Pharmacokinetics of DBD. Eur J Cancer Clin Oncol 18:1211–1219Google Scholar
  37. 37.
    Kato T, Nemato R, Nishimoto T, Kumagai I, Miura K (1979) Chemosensitivity of human bladder cancer cells in long-term culture and clinical responses to the selected anticancer drug. Cancer 44:58–63Google Scholar
  38. 38.
    Kikwood JM, Ensminger W, Rosowsky A, Papathanasopoulos N, Frei E (1980) Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a phase I trial Cancer Res 40:107–113Google Scholar
  39. 39.
    Mattsson W, Tropé C, Orbert B (1980) A phase I study of Spirogermanium. Proc Am Assoc Cancer Res 21:194Google Scholar
  40. 40.
    Morgan BDG, Holden J, Dewey DL, Riley PA (Unpublished results)Google Scholar
  41. 41.
    Oken MM, Crooke ST, Elson MK, Strong JE, Shafer RB (1981) Pharmacokinetics of bleomycin after 1 M administration in man. Cancer Treat Rep 65:485–489Google Scholar
  42. 42.
    Oliver RTD, England HR, Risden RA, Blandy JP (1984) Methotrexate in the treatment of metastatic and recurrent primary transitional cell carcinoma. J Urol 131:483–485Google Scholar
  43. 43.
    Patton TF, Himmelstein KJ, Belt R, Bannisters SJ, Sternson LA, Repta AJ (1978) Plasma levels and urinary excretion of filterable platinum species following bolus injection and IV infusion of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 62:1359–1362Google Scholar
  44. 44.
    Pinedo HM, Bocken MCYM, Gall HE, Den Hartigh J, Van Oort WJ (1982) Analysis and pharmacokinetics of mitomycin C. In: Ogawa M, Rozencweig M, Stavquet MJ (eds) Mitomycin C: Current impact on cancer chemotherapy. Excerpta Medica, Amsterdam Princeton Geneva Tokyo, pp 25–29Google Scholar
  45. 45.
    Reynolds DL, Ulrich KK, Patton TF, Repta AJ, Sternson LA, Myron MC, Taylor SA (1981) Plasma levels of 1,4-dihydroxy-5,8-bis ({2-[(2-hydroxylethyl) aminoll]ethyl}amino)-9,10-anthracenedione dihydrochloride (DHAD) in humans. Int J Pharm 9:67–71Google Scholar
  46. 46.
    Roper PR, Drewinko B (1976) Comparison of in vitro methods to determine drug-induced cell lethality. Cancer Res 36:2182–2188Google Scholar
  47. 47.
    Runiak HT, Dennis LY, Hill BT (1983) An intercomparison of in vitro assays for assessing cytotoxicity after a 24 hour exposure to anti-cancer drugs. Tumori 69:37–42Google Scholar
  48. 48.
    Shrivastav S, Paulson DF (1980) In vitro chemotherapy testing of transitional cell carcinoma. Invest Urol 17:395–400Google Scholar
  49. 49.
    Smith IE (1983) Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 10:103–115Google Scholar
  50. 50.
    Vermorken JB, Van Der Vijgh WJF, Klein I, Gall HE, Pinedo HM (1982) Pharmacokinetics of free platinum species following rapid, 3 hr and 24 hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. Eur J Cancer Clin Oncol 18:1069–1074Google Scholar
  51. 51.
    Yagoda A (1980) Chemotherapy of metastatic bladder cancer. Cancer 45:1879–1888Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • P. J. Hepburn
    • 1
  • R. T. D. Oliver
    • 2
  • P. A. Riley
    • 3
  • B. T. Hill
    • 4
  • J. R. W. Masters
    • 1
  1. 1.Department of HistopathologySt. Paul's Hospital, Institute of UrologyLondonUK
  2. 2.Department of OncologySt. Paul's Hospital, Institute of UrologyLondonUK
  3. 3.Department of Biochemical PathologyUniversity College Medical SchoolLondonUK
  4. 4.Laboratory of Cellular Chemotherapy, Imperial Cancer Research FundLincoln's Inn FieldsLondonUK

Personalised recommendations